Korro Bio Inc (KRRO) - News Archive

Breakthrough in Alpha-1 Antitrypsin Deficiency: Korro s KRRO-110 Receives Green Light for Clinical TrialsIn an exciting development for the treatment of Alpha-1 Antitrypsin Deficiency (AATD), Korro Bio has announced tha...

: Korro Bio, Inc. (Nasdaq: KRRO), a biopharmaceutical company dedicated to the advancement of innovative genetic medicines for a range of rare and common diseases, has recently marked significant milestones in its strat...

In a recent announcement, Korro Bio has forged a strategic partnership with pharmaceutical giant Novo Nordisk, focusing on the development of two therapeutic candidates aimed at addressing cardiometabolic diseases. This...

Korro Bio Joins Prestigious Russell Indexes, Amplifying Its PotentialCAMBRIDGE, Mass., July 01, 2024 - Korro Bio, Inc. (Nasdaq: KRRO), an innovative biopharmaceutical company specializing in developing groundbreaking ge...

A Promising Frontier: Preclinical Advances of KRRO-110 for Alpha-1 Antitrypsin Deficiency Korro Bio, Inc., a notable name in the burgeoning field of RNA editing technologies, has recently presented compelling preclinica...

Korro Bio, a prominent biopharmaceutical company headquartered in Cambridge, Massachusetts, recently made an exciting announcement regarding its plans to raise $70 million in a private placement. The company, focused on...

Korro Bio, Inc. (KRRO) has emerged as a leading biopharmaceutical company with a primary focus on developing groundbreaking genetic medicines for rare and prevalent diseases. In their recent press release on March 26, 2...

Korro Bio Presents Promising Data for its Genetic Medicines in Alpha-1 Antitrypsin Deficiency and Advances in RNA Editing PortfolioKorro Bio, a leading biopharmaceutical company based in Cambridge, Massachusetts, made a...